Interdisciplinary Dialogue on the Treatment of Cardio-metabolic Syndrome (31 January – 1 February 2025, Bratislava): report

Czech version

Authors: Zbynek Schroner
Authors‘ workplace: Lekárska fakulta, Univerzita Pavla Jozefa Šafárika v Košiciach
Published in: Diab Obez 2025; 25(1): 59-62
Category: News

Sources

Packer M, Anker SD, Butler J et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383(15): 1413–1424. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2022190>.

Anker SD, Butler J, Filippatos G et al. [EMPEROR-Preserved Trial Investigators]. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385(16): 1451–1461. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2107038>.

Herrington WG, Staplin N, Wanner C et al. [EMPA-KIDNEY Collaborative Group]. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388(2): 117–127. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2204233>.

Zinman B, Wanner C, Lachin JM et al. [EMPA-REG OUTCOME Investigators]. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.

Fitchett D, Zinman B, Inzucchi SE et al. Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial. Cardiovasc Diabetol 2024; 23(1): 248. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933–024–02328–6>.

Patorno E, Pawar A, Franklin JM et al. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. Circulation 2019; 139(25): 2822–2830. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.118.039177>.

Melzer-Cohen C, Schechter M, Rozenberg A et al. Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease. Clin J Am Soc Nephrol 2023; 18(9): 1153–1162. Dostupné z DOI: <http://dx.doi.org/10.2215/CJN.0000000000000218>.

Claggett B, Lachin JM, Hantel S et al. Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. Circulation 2018; 138(15): 1599–1601. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.118.033810>.

Fernández-Fernandez B, Sarafidis P, Soler MJ et al. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J 2023;16(8): 1187–1198. Dostupné z DOI: <http://dx.doi.org/10.1093/ckj/sfad082>.

[Ministerstvo zdravotnictva SR]. Zoznam kategorizovaných liekov 1. 9. 2024–30. 9. 2024. Dostupné z WWW: <https://health.gov.sk/Clanok?lieky202409>.